Alpha-9 Oncology is a clinical-stage radiopharmaceutical company based in Vancouver. The company develops targeted molecules for precision cancer therapy and describes its approach as optimizing each component of the radiopharmaceutical molecule, including the binder, linker, chelator, and radioisotope. Alpha-9 positions itself squarely in precision oncology with in-house formulation expertise and purpose-built radiopharmaceutical infrastructure.